PERMIXON® 160 mg hard capsule versus placebo in the treatment n the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia
PERMIXON® 160 mg hard capsule versus placebo in the treatment n the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia
Permixon® in LUTS Evaluation Study (PERLES)
PERMIXON® 160 mg hard capsule versus placebo in the treatment n the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia
Status
Status :
Completed
Type of study
Phase IV
Min. Age
45
Years old
Max. Age
85
Years old
Gender
Male
Therapeutic area :
Urology
Disease :
Benign Prostate Hypertrophy
Study medication :
Permixon®
Phase :
Phase IV
Start Date :
07 May 2014
End date :
27 June 2016
Study ID :
P00048 GP 404
EudraCT/CTIS number :
2014-000222-38
CT.gov Number :
NCT02121613
Send by email